Wird geladen...
Differentiating mTOR Inhibitors in Renal Cell Carcinoma
PI3K/Akt/mTOR signalling is dysregulated in many cancers, including renal cell carcinoma (RCC), and activation of this pathway has been suggested to correlate with aggressive behavior and poor prognosis in RCC tumors. mTOR inhibition plays a principal role in the targeted treatment of many cancer ty...
Gespeichert in:
| Veröffentlicht in: | Cancer Treat Rev |
|---|---|
| Hauptverfasser: | , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
2013
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4957946/ https://ncbi.nlm.nih.gov/pubmed/23433636 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ctrv.2012.12.015 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|